Research programme: immunotherapies - ImmunoCellular Therapeutics

Drug Profile

Research programme: immunotherapies - ImmunoCellular Therapeutics

Alternative Names: dendritic cell immunotherapies - Immunocellular therapeutics; Notch and numb pathway immunotherapies - ImmunoCellular Therapeutics

Latest Information Update: 11 Aug 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator ImmunoCellular Therapeutics
  • Class Cancer vaccines; Dendritic cell vaccines; Peptide vaccines; Stem cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 09 Aug 2016 Preclinical development is on-going for Solid-tumours in USA (Parenteral)
  • 16 Feb 2016 ImmunoCellular Therapeutics enters into a research agreement with Stanford University
  • 28 Jan 2016 ImmunoCellular Therapeutics, University of Maryland School of Medicine and University of Maryland agree to co-develop dendritic cell immunotherapies in USA for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top